Markets:

Overview

News

Currencies

International

Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

33.58 +0.42 (+1.27%)

Streaming Delayed Price Updated: 11:00 AM EST, Feb 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

7 Healthcare Stocks That Are Poised to Become the Next Unicorns ↗

November 09, 2023

Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments.

Via InvestorPlace

For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering. ↗

November 07, 2023

ALKERMES PLC (NASDAQ:ALKS) stands out as a growth opportunity that won't break the bank.

Via Chartmill

NASDAQ:ALKS, an undervalued stock with good fundamentals. ↗

October 26, 2023

ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Why Alkermes Stock Is Sinking Today ↗

October 25, 2023

The biotech company's Q3 revenue and earnings looked great, but the results weren't enough to wow investors.

Via The Motley Fool

Alkermes Q3 Earnings Top Consensus, On Track To Separate Oncology Business, Reaffirms FY23 Outlook ↗

October 25, 2023

Alkermes PLC (NASDAQ: ALKS) reported Q3 FY23 adjusted EPS of $0.64 compared to $0.02 a year ago, beating the

Via Benzinga

Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone. ↗

October 23, 2023

Analysts say Alkermes' drug is clearly active. But investors have concerns.

Via Investor's Business Daily

Why NASDAQ:ALKS Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

October 23, 2023

ALKERMES PLC (NASDAQ:ALKS), a strong growth stock, setting up for a breakout.

Via Chartmill

Earnings Preview: Alkermes ↗

July 25, 2023

Via Benzinga

Where Alkermes Stands With Analysts ↗

June 07, 2023

Via Benzinga

Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

October 25, 2023

Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ.

Via Benzinga

While growth is established for NASDAQ:ALKS, the stock's valuation remains reasonable. ↗

October 17, 2023

Looking for growth without the hefty price tag? Consider ALKERMES PLC (NASDAQ:ALKS).

Via Chartmill

Alkermes Earnings Perspective: Return On Capital Employed ↗

April 27, 2023

Via Benzinga

Analyst Expectations for Alkermes's Future ↗

April 27, 2023

Via Benzinga

The Latest Analyst Ratings for Alkermes ↗

April 27, 2023

Via Benzinga

A Preview Of Alkermes's Earnings ↗

April 25, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗

October 24, 2023

Via Benzinga

NASDAQ:ALKS is showing good growth, while it is not too expensive. ↗

September 26, 2023

Despite its growth, ALKERMES PLC (NASDAQ:ALKS) remains within the realm of affordability.

Via Chartmill

Hovnanian Enterprises, LexinFintech Holdings And Other Big Stocks Moving Higher On Wednesday ↗

August 30, 2023

U.S. stocks traded mixed, with the Dow Jones falling around 10 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Earnings Scheduled For February 16, 2023 ↗

February 16, 2023

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...

Via Benzinga

Alkermes Earnings Preview ↗

February 15, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗

October 17, 2023

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 17, 2023

Via Benzinga

3 Top Biotech Stocks Defying the Bear Market ↗

August 10, 2023

Biotech is still booming, if you pick the right biotech stocks.

Via The Motley Fool

Alkermes Clocks Over 100% Jump In Q2 Sales and Profits On Reinstated Product Royalty From Long-Acting Invega ↗

July 26, 2023

Alkermes plc (NASDAQ: ALKS) reported Q2 adjusted EPS of $0.55 compared to $0.06 a year ago, missing the consensus of $0.56

Via Benzinga

Alkermes Raises FY23 Outlook Following Arbitration Award from Janssen Agreements ↗

June 06, 2023

Via Benzinga

Alkermes Stock Sees Rising Relative Strength Rating ↗

March 28, 2023

The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77.

Via Investor's Business Daily

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Alkermes: Commercialization Program On Track, Sales Coming In Strong ↗

March 04, 2023

The bigger biotechs have done a good job lately, with solid earnings to date. Speaking of which, Alkermes plc has recently exceeded estimates. Let's take a closer look at the company's performance.

Via Talk Markets

Alkermes Stock Sees Rising Relative Price Strength ↗

February 17, 2023

The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86.

Via Investor's Business Daily

Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out ↗

February 16, 2023

Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.